AGTC CEO to present at Cell & Gene Meeting on the Mesa

By The Science Advisory Board staff writers

October 12, 2021 -- Biotechnology firm Applied Genetic Technologies (AGTC) President and CEO Sue Washer will present at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, on October 13 at 11:15 a.m. PT.

AGTC conducts human clinical trials of adeno-associated virus-based gene therapies for the treatment of rare inherited retinal diseases.

Washer will provide a corporate update and talk about AGTC's plans to move late-stage X-linked retinitis pigmentosa and achromatopsia clinical programs forward, the company said.

AGTC expands gene therapy manufacturing capabilities
Applied Genetic Technologies (AGTC) has initiated plans to lease a build-to-suit 21,000-sq-ft current good manufacturing practice manufacturing and quality...
AGTC touts positive early clinical results for gene therapy
Applied Genetic Technologies (AGTC) has reported positive data from its ongoing phase I/II clinical trial evaluating its adeno-associated virus (AAV)-based...
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter